Overview of Arachidonic Acid Metabolism and the Pro-Resolving Lipid Mediators
=============================================================================

Inflammation is a pathophysiologic process that occurs in the context of broad spectra of stimuli and diseases including arthritis, asthma, trauma, and infection. During acute infection, inflammation is protective, but if it is excessive or prolonged, it harms the host, damaging tissues and impairing proper repair, and in extreme cases, it can be lethal. Repair and restoration of normal organ function are essential after an infectious disease, and these processes are accomplished after the inflammatory events are appropriately resolved. However, resolution of inflammation is a more intricate process than the mere dissipation of chemoattractant signals. It includes a set of complex events mediated by several signals, including negative feedback regulation of Toll-like receptor (TLR) signaling, production of anti-inflammatory cytokines such as interleukin (IL)-10, and biosynthesis of a superclass of novel mediators. These newly discovered mediators include biochemical species derived from lipids such as lipoxins (LXs), resolvins (Rvs), protectins (PDs), and maresins ([@B116]), proteins such as Annexin A1 ([@B131]) and Galectin-1 ([@B132]), anti-inflammatory neuropeptides such as melanocortin (MC) peptide ([@B37]; [@B4]), and gasotransmitters such as hydrogen sulfide and carbon monoxide ([@B138]; [@B122]). The concerted actions of these molecules stop leukocyte recruitment, modify cytokine production, facilitate efferocytosis, switch macrophages to a non-phlogistic phenotype, and finally, promote healing to restore organ function ([@B118]).

Specialized pro-resolving mediators (SPMs), including the pro-resolving lipids, are produced via cell--cell interactions within the inflammatory exudates that control the magnitude and duration of local inflammation ([@B119]). SPMs are all products of the lipoxygenase (LO) pathway, though the lipid substrates vary (**Figure [1](#F1){ref-type="fig"}**).

![Biosynthetic pathways of specialized pro-resolving mediators.](fmicb-09-01961-g001){#F1}

SPMs Synthesis
--------------

### Lipoxins

Lipoxins are eicosanoids derived from omega-6 arachidonic acid (AA), which is oxygenated at position 15 by 15-LO activity to produce 15S-hydroperoxyeicosatetraenoic acid (15S-H(p)ETE). The product of 5-LO's action on 15-HpETE is a 5S-hydroperoxy,15S-hydro(peroxy)-DiH(p)ETE, which is rapidly converted to 5(6)-epoxytetraene. In turn, 5(6)-epoxytetraene is rapidly hydrolyzed to lipoxin A4 (LXA~4~) and LXB~4~ ([@B116]). Alternatively, acetylsalicylic acid (ASA)-acetylated cyclooxygenase 2 (COX-2) produces 5-*R*-Hydroxyeicosatetraenoic acid (5-*R*HETE) from AA. 5-*R*HETE is a substrate of 5-LO that can be converted to 15-epi-lipoxin A4 (15-epi-LXA~4~), which is also named ASA-triggered lipoxin (ATL) ([@B116]).

### Resolvins

On the other hand, Rvs, PDs, and maresins are derived from omega-3 polyunsaturated fatty acids. There are two series of Rvs depending on the lipid substrate and enzyme activities: Rv D and E. The RvD1--4 series, as well as PDs and maresins, are derived from docosahexaenoic acid (DHA) metabolism involving 12-LO and 15-LO, and the E-series Rvs are derived from the activity of ASA-acetylated COX-2 using eicosapentaenoic acid (EPA) as a substrate ([@B117]). Nevertheless, ASA can also trigger the COX-2-mediated conversion of DHA to 17R-HDHA, which 5-LO can covert to ASA-triggered Resolvin D1--4 (AT-RvD1--4) ([@B117]).

Drug Induction of SPMs
----------------------

As mentioned, ASA modifies COX-2 activity allowing 15-epi-LXA4 and AT-RvD1--4 production. Indeed, ASA-triggered resolving lipids are more stable than the endogenous molecules and could serve as anti-inflammatory drugs. Another fascinating group of drugs, statins, can also increase the production of pro-resolving lipids, in a way that is similar to the process mediated by ASA. Just as the acetylation of COX-2 by ASA causes a metabolic switch in COX-2, statins produce the same metabolic switch by nitrosylation. Recently, Serhan's group reported the presence of another subtype of Rvs, 13-series Rvs, which provide protective activity against *Escherichia coli* infections. These lipids are produced by COX-2 in a process involving a neutrophil--endothelium interaction, and their production can also be triggered by nitrosylation induced by atorvastatin ([@B34]). Thus, the change in COX-2 activity explains, at least in part, the anti-inflammatory properties of ASA and statins.

The Inflammation Resolution Crossroad
-------------------------------------

It is remarkable how the same enzymatic array participates in the generation of both inflammatory and resolving mediators. COX and LO activities, which are responsible for the production of prostaglandins (PGs) and leukotrienes, respectively, can switch to the production of LX, Rvs, PDs, and maresins. Indeed, AA derivatives, PGs E~2~ (PGE~2~), prostacyclin (PGs I2, PGI~2~), and leukotriene B~4~ (LTB~4~), participate in leukocyte recruitment to the damaged site. However, as acute inflammation progresses, a metabolic switch occurs, and LX synthesis begins. The exact moment when this switch happens is unclear; however, the dampening of the inflammatory signals may be part of the input needed to promote the metabolic changes ([@B48]). These switches are accomplished by transcriptional or posttranslational modifications, which involve PGE~2~ and PGs D~2~ (PGD~2~) ([@B47]; [@B33]). COX-mediated production of PGD~2~ by human PGD~2~ synthase (hPGD~2~s) activates the PGD~2~ receptor, DP~1~ (a G-protein coupled receptor \[GPCR\]), which in turn stimulates the production of IL-10 (an anti-inflammatory cytokine), which then blocks the path to chronic inflammation. PGD~2~ can also be converted to PGs J2 (PGJ~2~) and 15-deoxy-Δ(12,14)-PGs J~2~ (15-D-PGJ~2~) products that activate peroxisome proliferator-activated receptor (PPAR)-γ to promote resolution ([@B33]).

SPMs Mode of Action
-------------------

The actions of LXA~4~ are mediated by a GPCR called formyl peptide receptor 2/lipoxin A~4~ receptor (FPR2/ALXR), via several signaling pathways, including the p38/mitogen-activated protein kinase (MAPK)-activated protein kinase (APK)/heat shock protein 27 (HSP27), c-Jun N-terminal kinase (JNK), and phosphatidylinositol 3-kinase (PI3K) pathways ([@B31]), depending on the cell type. In monocytes and macrophages, LXA~4~ triggers the synthesis of IL-10 ([@B127]), a cytokine responsible for driving the resolution of inflammation, and enhances non-phlogistic phagocytosis of apoptotic cells ([@B72]). Also, some effects of LXA~4~ are related to its ability to activate the cytosolic aryl hydrocarbon receptor (AhR), inducing the expression of suppressor of cytokine signaling (SOCS) ([@B69]).

The action of Resolvin E1 (RvE1) is intricate because it is an agonist of the seven-pass transmembrane GPCR ChemR23. Naturally, the activation of ChemR23 by low concentrations of chemerin, its natural agonist, favors chemoattraction of monocytes/macrophages and immature dendritic cells (DCs). Activation of ChemR23 increases intracellular calcium release and inhibits cAMP and MAPK extracellular signal-regulated protein kinases 1/2 (ERK1/2)-mediated signaling, by Gi/o protein (a G protein subtype) recruitment. Consequently, it leads to up-regulation of the PI3K/Akt signaling pathway and down-regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) ([@B77]). RvE1, via a different set of G proteins, stimulates Akt phosphorylation and ribosomal protein S6 kinase ([@B89]). Also, RvE1 is a partial agonist of the LTB~4~ receptor 1 (BLT1) and competes with LTB~4~ for binding ([@B10]).

RvD1 can activate FRP2/ALXR and the G protein-coupled receptor 32 (GPR32) ([@B63]). The activation of the FPR2/ALX receptor by RvD1 suppresses cytosolic calcium and decreases activation of the calcium-sensitive kinase calcium-calmodulin-dependent protein kinase II (CaMKII). CaMKII inhibition suppresses activation of p38 and the MAP kinase-APK 2 (MAPK-APK2), which reduces Ser^271^ phosphorylation of 5-LO and shifts 5-LO from the nucleus to the cytoplasm ([@B45]). Moreover, LXA~4~ and RvE1 counter-regulate the LTB~4~/LL-37 proinflammatory circuit, which is partially mediated by FPR2/ALX ([@B139]).

Physiologic Actions of SPMs
---------------------------

LXA~4~ decreases polymorphonuclear leukocyte (PMN)-mediated tissue damage, angiogenesis, and PMN proliferation and adhesion, increasing non-phlogistic phagocytosis and IL-10 production ([@B25]). RvE1 increases PMN apoptosis, LXA~4~ production, and microbial killing, and decreases IL-12 production, PMN transendothelial migration, and PMN infiltration; also, it inhibits NF-κB reporter gene activation and reduces organ fibrosis ([@B10]; [@B19]; [@B38]). RvD1 decreases reactive oxygen species (ROS) generation and the production of pro-inflammatory cytokines. RvD1 also reduces organ fibrosis ([@B102]; [@B82]). RvD2 increases microbial killing and clearance, as well as the production of nitric oxide (NO•) and PGI~2~ in endothelial cells ([@B128]; [@B28]). PD1 decreases COX-2 expression, T-cell migration, and cytokine production, including that of TNF, IFN-γ, and microglial cell cytokines ([@B9]; [@B101]). Also, PD1 has neuroprotective actions ([@B120]). Maresins increase tissue regeneration, stimulating phagocytosis and the killing of oral pathogens by human leukocytes, and also promote the macrophage phenotype switch from M1 to M2 ([@B140]). It is important to emphasize that both Rvs and LXs promote bacterial clearance; thus, they both constitute a pathway that impedes microorganism evasion of the immune response. Thus, the concert of the SPMs in the inflammatory broth give a change of helm heading toward a calmer environment, where leukocyte and macrophage hyperactivity decline, promoting a favorable environment for the repair.

Role of SPMs in Chronic Infectious Diseases
-------------------------------------------

Infections may progress toward chronicity due to dysregulation of the inflammatory process. Thus, extensive damage may occur involving irreversible structural alterations. Furthermore, it has been shown that in chronic inflammatory states such as Alzheimer's disease ([@B141]), periodontitis ([@B134]), peripheral artery disease ([@B82]), or cystic fibrosis ([@B59]), the levels of pro-resolving factors such as LXA~4~, or ATLs are decreased. Therefore, it is suggested that a deficit of resolutory ability promotes chronic inflammatory states. Evidence of the participation of lipid pro-resolving mediators in infectious diseases is abundant. For example, in experimental models of lung infections (e.g., disseminated influenza A), there is low expression of LX ([@B29]), and exogenous administration of PD1 improves survival ([@B85]). Moreover, when inflammation persisted in a respiratory syncytial virus lung infection, and exogenous administration of LXs or Rvs reverses the inflammation ([@B123]). In a self-resolving murine model of *E. coli* pneumonia, exogenous AT-RvD1 administration enhanced the clearance of *E. coli* and *Pseudomonas aeruginosa in vivo*, and lung macrophage phagocytosis *ex vivo* ([@B2]). These findings were similar to the results of a lung coinfection model with *Streptococcus pneumoniae* and influenza A virus ([@B142]), which showed that AT-RvD1 decreased the inflammatory drive by acting on the FPR2/ALX receptor and antagonizing the effect of serum amyloid A, which is an agonist of this receptor. Thus, there is a clear relationship between bacterial or viral infection and SPMs generation.

However, the LXs-bacterial interplay in a chronic infection may be more complicated. In a mouse model of *Mycobacterium tuberculosis* infection, 5-LO knockout mice were more likely to survive compared with wild-type mice, which had a more protracted disease evolution. Administration of LXA~4~ inhibited the development of a Th1 response, which is protective in the tuberculosis model ([@B12]). Bacteria may also inhibit the resolution of infectious processes. A recent report demonstrated that chronic *P. aeruginosa* infections in cystic fibrosis patients promote the hydrolysis of an endogenous epoxide-containing eicosanoid 14,15-epoxyeicosatrienoic acid (14,15-EET) to its corresponding diol, thereby destroying the signal that triggers increased biosynthesis of 15-epi-LXA~4~ and preventing the activation of resolution pathways that could help to eradicate the infection ([@B43]).

Specialized pro-resolving mediators may contribute to eradicate infections and terminate the inflammatory input, as it is suggested by murine sepsis models, where there was reported that LXA~4~ decreased plasma IL-6, chemokine (C--C motif) ligand 2 (CCL2), IL-10, and NF-κB activity in peritoneal macrophages, reduced neutrophil migration, and increased the clearance of bacteria by neutrophils without the production of excessive free radicals ([@B137]; [@B145]). Furthermore, LX may increase the production of antibacterial proteins. Bactericidal/permeability-increasing protein (BPI) is increased in an *in vitro* model of *Salmonella typhimurium* infection when LXs are administered ([@B21]). Thus, LX may have a role in the clearance of pathogenic microorganisms. Interestingly, LXA~4~ decreases the release of the exotoxin pyocyanin by *P. aeruginosa*, reducing its pathogenicity ([@B144]). Thus, LXA~4~ also affects infective agents. Furthermore, RvD1 and RvD5 were shown to decrease the dose of antibiotics needed to treat *E. coli* or *Staphylococcus aureus* infections ([@B28]). Thus, RvD1 and RvD5 can help to clear bacteria and, most importantly, this research provides new insight into how to circumvent antibiotic resistance ([@B28]).

In addition to its action in bacterial infections, LXA~4~ plays a role in acute and chronic parasitic infections. However, it is controversial because in murine models of cerebral malaria, LXA~4~ is associated with a lower parasite burden, less cerebral inflammation, and better survival ([@B124]). However, in a murine model of *Toxoplasma gondii* infection, although LXA~4~ production is increased and there is less cerebral inflammation (due to decreased IL-12 levels), the immune response against the parasite is dampened ([@B5]). Probably, this despair results are due to the distinct causative organism or by the inflammatory context where LXA~4~ was produced.

*Trypanosoma cruzi* Infections
==============================

*Trypanosoma cruzi* is a flagellate protozoan that causes Chagas disease (CD). The life cycle of the parasite includes survival inside muscle cells, including cardiac muscle and smooth muscle of the gastrointestinal tract ([@B104]). The infection process involves an intense inflammatory response, which is coordinated by pro-inflammatory mediators such as PGs ([@B24]; [@B22]), leukotrienes, cytokines, and chemokines that increase the expression of endothelial cell adhesion molecules (ECAMs), allowing the migration of immune cells to the infection site ([@B49]). The increase in ECAMs induces vascular permeability and leukocyte recruitment ([@B50]). These events are pivotal in the pathogenesis of chronic Chagas cardiomyopathy (CCC, the most lethal form of CD) because they facilitate leukocyte adhesion to cardiac endothelial cells and cause endothelial dysfunction. In turn, endothelial dysfunction is associated with focal ischemic events and microvascular abnormalities. Additionally, in CCC, the observed microvascular damage is worsened by platelet aggregation, which is activated by thromboxane A~2~ (TXA~2~), promoting a procoagulant environment that could exacerbate the focal ischemia ([@B22]; [@B1]; [@B110]; [@B100]). Thus, if left untreated, low-grade myocarditis initially ensues and the infection progresses from the acute to the chronic stage without necessarily involving clinical manifestations. As the infection and endothelial dysfunction persist, a myocardial remodeling process is launched, establishing CCC. Consequently, 30% of infected individuals develop cardiac complications, which can induce death by heart failure ([@B104]; [@B107]).

Role of SPMs in Acute Chagas Disease
------------------------------------

Among the acute inflammatory mediators, AA derivatives have been described as essential drivers of the acute infection process and the chronic cardiac damage induced by the parasite. Experimental *in vivo* models of infection with *T. cruzi* showed an increase in the expression of COX-2 ([@B83]) and PGs E receptor 2 (EP~2~) in cardiac tissue ([@B52]). These proteins are involved in the synthesis and activity of AA derivatives, such as PGE~2~, TXA~2~, PGF~2α~, 6-oxo-PGF~1α~, LTB~4~, and other eicosanoids that have been observed increased after *T. cruzi* infection. Consequently, cells derived from *T. cruzi*-infected mice shows elevated levels of PGE~2~ ([@B24]; [@B15]; [@B46]; [@B52]). Also, PGE~2~, TXA~2~, PGI~2~, PGF~2α~, and LTB~4~ levels have been found increased in plasma of mice infected with *T. cruzi* ([@B22]; [@B83],[@B84]; [@B121]). Also, it is well-documented that *T. cruzi* itself can synthesize AA derivatives like TXA~2~, PGE~2~, and PGF~2α~ by the action of the *T. cruzi* old yellow enzyme (TcOYE) ([@B65]; [@B11]). There is evidence that both, host- and parasite-derived autacoids contribute importantly to cardiac remodeling. In fact, COX-2, PLA2γ, or 5-LO deficient mice, infected with *T. cruzi*, exhibited improved survival rate and reduced cardiac tissue inflammation when compared with wild-type mice ([@B24]; [@B15]; [@B22]). Furthermore, there is evidence indicating that *T. cruzi* induces the formation of lipid bodies, specialized organelles where PGs synthesis occurs, being an important strategy for parasite growth and survival ([@B79]; [@B35]). The effect of the host or parasite-derived AA derivatives in the acute infection onset has been reviewed extensively elsewhere ([@B70]).

15-D-PGJ~2~ Is Pro-resolving in *T. cruzi* Infection
----------------------------------------------------

An aspect of growing interest is the implication of the PPAR-γ pathway in the modulation of inflammatory processes in chronic infections ([@B61]). In this regard, this pathway is related to the decrease in the transcription of genes controlled by NF-κB and the activator protein-1 (AP-1). It is well known that 15-D-PGJ~2~, which is a pro-resolving lipid derived from PGD~2~, acts as an agonist of PPAR-γ ([@B93]). Therefore, it may have a role in pro-resolving processes in conjunction with other SPMs. Consequently, 15-D-PGJ~2~ has been tested as a modulator of acute and chronic heart inflammation in *T. cruzi* infection. 15-D-PGJ~2~ (1 mg/kg) decreases the inflammatory infiltrate and amastigote nest count and significantly increases the IL-10 levels ([@B108]). Also, 15-D-PGJ~2~ attenuates acute liver damage induced by *T. cruzi* in mice. In this model, 15-D-PGJ~2~ was able to decrease fibrosis and liver damage without influencing the course of the infection itself ([@B95]). Moreover, a preliminary report from the same group suggested that treatment with 15-D-PGJ~2~ could regulate the number of intracellular amastigotes in the cardiac tissue via PPAR-γ-dependent and PPAR-γ-independent pathways ([@B94]).

Acetylsalicylic Acid in Acute and Chronic Chagas Disease
--------------------------------------------------------

Due to the role of AA derivatives in *T. cruzi* infection, inhibition of COX activity has been proposed as a strategy for controlling parasite-induced disease. Although several non-steroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, meloxicam, and celecoxib, have been assayed in mouse models of *T. cruzi* infection ([@B46]; [@B80]; [@B1]; [@B57]), the most studied NSAID is ASA, also known as aspirin. Interestingly, the effect of ASA seems to be mouse-species dependent. When *T. cruzi*-resistant mice (C57BL/6 or CD-1) are treated with ASA, parasitemia and mortality increases ([@B80]; [@B57]; [@B86]). On the other hand, Balb/c mice, which are sensitive to *T. cruzi* infection, become healthy when ASA is administrated ([@B46]; [@B91]; [@B57]). Importantly, C57BL/6 mice generate more NO• than Balb/c mice after *T. cruzi* infection, and ASA treatment induces NO• production in Balb/c mice infected with *T. cruzi* ([@B57]). Furthermore, in murine macrophages infected with *T. cruzi*, the inhibition of NO• synthesis partially prevents the effect of ASA ([@B68]), suggesting an important role for this mediator in the ASA effect.

More importantly, the effect of ASA has an important relationship with its dose. Most studies investigating ASA have been performed using a fixed dose of 25--50 mg/kg. However, studies using higher doses (\>75 mg/kg) have shown no effect, or they have shown that ASA aggravates the damage caused by intraperitoneal or oral *T. cruzi* infection ([@B83]; [@B32]). The fact that ASA has an antichagasic effect only at doses \<50 mg/kg has been associated to the production of 15-epi-LXA~4~, an ASA-triggered LX found in patients treated with low doses of ASA ([@B27]). In Balb/c *T. cruzi*-infected mice, 25 and 50 mg/kg of ASA induced a significant increase in 15-epi-LXA~4~ production without modification of LTB~4~ levels. At these doses, the mice had prolonged survival, decreased mortality, and less cardiac inflammatory infiltrate. Additionally, the administration of 25 mg/kg exogenous 15-epi-LXA~4~ significantly decreased the parasitemia peaks and cardiac parasite load, improved the survival of the infected mice, and partially reversed the detrimental effect of high-dose ASA ([@B83]). Low doses of ASA also improve the vascular reactivity of mice infected with *T. cruzi*. [@B84] evaluated the effect of ASA at 2 and 40 mg/kg and found that both regimens decreased ECAM expression and the TXA~2~ level. Also, 2 mg/kg/day ASA reduced the inflammatory infiltrate in mice hearts and improved the cardiac histology at 90 days post infection. Furthermore, in *in vitro* cardiac cells infected with *T. cruzi*, low doses of aspirin increased IL-1β and NO• release, and decreased transforming growth factor (TGF)-β release, and these effects disappeared when ASA concentrations were increased ([@B75]).

Consistently, ATLs not only participate in the resolution of the damage produced by *T. cruzi* but also in the clearance of the pathogen. In an *in vitro* model of *T. cruzi*-infected macrophages, the addition of 0.3--1.25 mM of ASA significantly decreased the internalization of *T. cruzi* without altering macrophage viability ([@B23]). Also, it has been reported that 0.625--2.5 mM of ASA decreased the internalization of *T. cruzi* and increased the release of IL-15 and NO•. However, co-administration of celecoxib (a COX-2 selective inhibitor) reverted the ASA effect and restored the invasive capacity of trypomastigotes, suggesting that functional COX-2 is necessary for the ASA effect. Furthermore, Boc-2 (a specific antagonist of the FRP2/ALX receptor) prevented the ASA effect, suggesting that the inhibition of invasion depends on the synthesis of 15-epi-LXA~4~ ([@B74]).

The effects of other SPMs triggered by ASA have been studied. [@B88] evaluated the effect of AT-RvD1 on peripheral mononuclear cells (PBMCs) from patients with Chagas heart disease at stage B1, that is, with few heart abnormalities. Stimulation of PBMCs with a *T. cruzi*-derived antigen increased the production of INF-γ, TNFα, IL-10, and IL-13, while the pre-treatment of PBMCs with AT-RvD1 (100 nM) significantly reduced the production of INF-γ, with no changes in TNFα, IL-10, and IL-13. As INF-γ polarizes the immune response to a type Th1 response, and a low level of IL-10 indicates loss of the Treg response, both phenomena could be associated with the development of heart damage in CD. Therefore, decreasing INF-γ using AT-RvD1 has a beneficial role in chagasic cardiomyopathy. Furthermore, AT-RvD1 was able to reduce the percentage of necrotic PBMCs and their proliferation after stimulation with a *T. cruzi* antigen ([@B88]).

Recently, an elevated plasma level of RvD1 has been found in *T. cruzi*-infected CD-1 mice. Also, RvD1, RvD5, and RvE2 (but not LXs, maresins, or PDs) were found in the lysates of *T. cruzi* trypomastigotes. Interestingly, there were no Rvs found in the lysates of *T. cruzi* epimastigotes or other protozoan parasites such as *T. gondii*, suggesting that the trypomastigotes themselves synthesize these SPMs ([@B30]). However, there was no direct evidence for a metabolic switch involving TcOYE or a yet unknown enzymatic activity that could explain a *T. cruzi* origin of these SPMs. There is currently no evidence of a *T. cruzi* 5-LO enzyme or another enzyme for SPM synthesis.

Statins and SPMs in Chronic Chagas Disease
------------------------------------------

15-epi-LXA~4~ can also be produced by statins. [@B14] showed that statins stimulate 15-epi-LXA~4~ release from myocardial tissue. This effect of statins over COX-2 could be mediated by the overexpression of inducible NO• synthase (iNOS), which in turns nitrosilates COX-2 at the Cys^526^ residue, giving COX-2 the ability to generate the 15R-HETE intermediate metabolite, which is cleaved by 5-LO to generate 15-epi-LXA~4~ ([@B62]). This 15-epi-LXA~4~ production also requires that 5-LO remains in the cytoplasm. Thus, 5-LO, phosphorylated by protein kinase A (PKA) is attached to the nuclear membrane, where it is committed to leukotriene synthesis ([@B146]).

In *T. cruzi*-infected human endothelial cells, simvastatin induces the synthesis of 15-epi-LXA~4~ and decreases the ECAM expression induced by the parasite. This effect was reversed by the addition of AA-861 (a 5-LO inhibitor) and replicated when using exogenous 15-epi-LXA~4~. Interestingly, 15-epi-LXA~4~ inhibited NF-κB pathway activation, decreasing the phosphorylation of the NF-kappa-B inhibitor (IκB) and the IκB kinase (IKK), and preventing NF-κB p65 nuclear translocation. Thus, the action of 15-epi-LXA~4~ in *T. cruzi*-infected endothelial cells involves the NF-κB signaling pathway ([@B20]). In addition, in a murine model of CCC, 40 mg/kg/day simvastatin decreased endothelial activation, inflammatory infiltration, and fibrosis in heart tissue, an effect that persisted for a long time after treatment stopped. When simvastatin was administered to 5-LO-deficient mice, the anti-inflammatory effect was not observed unless exogenous 15-epi-LXA~4~ was also administered. Thus, there is an association between simvastatin administration, 15-epi-LXA~4~ production, and cardiac improvement. Furthermore, 15-epi-LXA~4~ was still detectable 30 days post administration, suggesting that 15-epi-LXA~4~ is stable in serum and is associated with the observed sustained effects ([@B51]).

**Table [1](#T1){ref-type="table"}** summarizes the experimental evidence showing the effect of pro-resolving mediators in *T. cruzi* infections *in vivo*. The findings support the idea that ASA and simvastatin have a positive impact on the resolution pathways, producing novel pro-resolving lipids such as 15-epi-LXA~4~ or AT-RvD1, modulating the inflammatory response, and decreasing ECAMs, leukocyte recruitment, and inflammatory infiltration. Also, the SPMs increase the survival rate in animal models of CD.

###### 

Experimental evidence on the role of pro-resolving mediators in Chagas disease.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pro-resolving mediator                Experimental model                                Beneficial role in Chagas disease                          Reference
  ------------------------------------- ------------------------------------------------- ---------------------------------------------------------- -------------------------
  15-epi-LXA~4~ (ASA-triggered)         Chronic model of Chagas cardiomyopathy            ↑ Survival\                                                [@B83]
                                                                                          ↓ Cardiac parasite load\                                   
                                                                                          ↓ Number of amastigote nests\                              
                                                                                          ↓ Inflammatory infiltration                                

                                        Peritoneal macrophages infected with *T. cruzi*   ↓ Internalization of *T. cruzi* into macrophages           [@B74]

  15-epi-LXA4 (simvastatin-triggered)   Endothelial cells infected with *T. cruzi*        ↓ CAM expression\                                          [@B20]
                                                                                          ↓ Cellular recruitment Effect dependent on NF-κB pathway   

                                        Chronic model of Chagas cardiomyopathy            ↓ CAM expression\                                          [@B51]
                                                                                          ↓ Inflammatory infiltration and fibrosis\                  
                                                                                          ↓ Cardiac parasite load Effect dependent on 5-LO           

  AT-Resolvin D1                        PBMC from patients with Chagas disease            ↓ INF-γ\                                                   [@B88]
                                                                                          ↓ Necrotic cells\                                          
                                                                                          ↓ Proliferation                                            

  15-D-PGJ2                             Acute model of mice infected with *T. cruzi*      ↓ Number of amastigote nests\                              [@B108]; [@B94], [@B95]
                                                                                          ↓ Inflammatory infiltration ↑ IL-10\                       
                                                                                          ↓TNF-α, IL-6, IL-1β, and NF-κB activation\                 
                                                                                          ↓ Liver fibrosis, CTGF, and TGF-β                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CAM, cellular adhesion molecules; 5-LO, 5-lipoxygenase; INF-γ, interferon-γ; TNF-α, tumor necrosis factor-α; IL, interleukin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; PBMC, peripheral blood mononuclear cell; CTGF, connective tissue growth factor.

*Leishmania* spp. INFECTIONS
============================

*Leishmania* spp. infections have become a paradigm to explain how the balance between Th1 and Th2 immune responses can effectively fight an intracellular parasite. In these infections, the Th1 response (mediated by TNF-α, IL-2, IL-12, and IFN-γ) exerts a protective role, while the Th2 response (mediated by IL-4, IL-5, and IL-10) is known as a disease promoter (reviewed in [@B78]). The clinical manifestations of leishmaniasis are divided into three forms: cutaneous, mucocutaneous, and visceral leishmaniasis (VL).

Cutaneous Leishmaniasis
-----------------------

Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis around the world. CL is characterized by self-limiting skin lesions located in body areas where sandflies usually bite, such as the face, neck, and limbs. The disease progression varies between different world regions. The old-world CL (caused by *Leishmania major* or *Leishmania tropica*) progresses over weeks to months to form a dry ulcer, but healing occurs over several months or years, leaving a scar or depigmentation of the skin. On the other hand, the new-world CL (caused by *Leishmania mexicana, Leishmania amazonensis*, or several parasites from the *Vianna* subspecies, such as *L. \[V\] braziliensis*) produces a wet ulcer that is associated with lymphadenitis or lymphadenopathy and may involve mucosal manifestations. New-world leishmaniasis is also called tegumentary leishmaniasis (TL), which can be localized or disseminated ([@B36]).

In patients with TL, there is a different pattern of expression of the genes involved in the AA cascade between patients with localized CL (LCL) and mucocutaneous leishmaniasis (MCL). Patients with MCL (the most inflammatory form, with a lower parasite burden per lesion) have decreased expression of the genes for PGE~2~ synthesis enzymes (*PTGS1* and *PGES*), whereas the expression of the gene for 5-LO (*ALOX5*) is increased. This divergent expression pattern correlates with the decreased levels of PGE~2~ and increased levels of LTB~4~ found in patients with MCL. Also, in this study, patients with MCL have increased expression of *PTGER3*, the gene coding for the PG receptor EP~3~ ([@B44]). This finding suggests a role for LTB~4~ in MCL-induced inflammation. However, studies on the role of the inflammatory AA derivatives (such as PGE~2~ or LTB~4~) at the molecular level show that this effect is highly *Leishmania* species-dependent (**Figure [2](#F2){ref-type="fig"}**).

![Overview of the regulation of inflammatory arachidonic acid (AA) derivatives after *Leishmania major* or *Leishmania amazonensis* infections. Cutaneous leishmaniasis causative parasites (*L. major* and *L. amazonensis*) induce the production of AA derivatives with opposite roles, depending on the *Leishmania* species. In *L. major* infection models (upper panel) the parasite induces the production of PGE~2~ and LTB~4~. Also, the expression of the EP~1~ and EP~3~ receptor is increased. The activation of these receptors by PGE~2~ leads to parasite survival. PGE~2~ also increases the release of IL-10 by the B1 cells, reducing the phagocytic activity of macrophages. On the other hand, *L. amazonensis* (lower panel) phagocytosis and killing by macrophages is increased by LTB~4~ and PGE~2~, and this effect is mediated by the NO• increase. Also, *L. amazonensis* increase the degranulation of neutrophils, increasing the anti parasitic activity of the immune system.](fmicb-09-01961-g002){#F2}

In the 1980s, it was reported that higher levels of PGE~2~ relate to reduced lymphocyte proliferation in the spleens of mice infected with *L. major* ([@B40]). Moreover, the increase in PGE~2~ and LTB~4~ levels induced a reduction in the Th1 cytokines TNF-α and IFN-γ, and an increase in the Th2 cytokine IL-4. This effect has been linked to the overexpression of the PG receptors EP~1~ and EP~3~ ([@B81]). Indeed, in macrophages from Balb/c mice infected with *L. major*, there is an increase in these receptors and downregulation of EP~2~ and EP~4~ receptors. Furthermore, agonists of EP~1~ and EP~3~ favor infection, whereas selective agonists of EP~2~ and EP~4~ decrease infection ([@B96]). PGE~2~ also affects the role of B-1 cells. B-1 cells modulate the phagocytic activity of macrophages; this action is dependent on IL-10 release, which in turn modulates the PGE~2~ levels in the media ([@B8]). Also, PGE~2~ (via IL-10 production) increases the phagocytic activity of Balb/c mice-derived B-1CDP cells (a particular B-1 cell type with phagocytic ability; [@B16]), but it impairs the ability of the mice to resist the infection ([@B7]). Finally, in a model involving human PMNs co-stimulated with ionomycin or LPS/N-formyl-methionyl-leucyl-phenylalanine (LPS/fMLP), *L. major* was also able to increase LTB~4~ release, which in turn induced a rapid and sustained decrease in LXA~4~ production ([@B98]).

In contrast, in mouse models of *L. amazonensis* infection, higher levels of LTB~4~ and PGE~2~ enhance the parasite-killing ability of murine macrophages, an effect that is dependent of NO• production and IL-10 reduction ([@B54]; [@B115]). The high levels of LTB~4~ from macrophages can also be induced by ATP, via P2X7 receptor activation ([@B26]). LTB~4~ also has a role in neutrophil-dependent *L. amazonensis* killing. LTB~4~ activates its BLT~1~ receptor, inducing neutrophil degranulation, the release of metalloproteinase 9 (MMP-9) and myeloperoxidase (MPO), ROS production, and overexpression of TLR2. All these phenomena may be associated with the activation of NF-κB, PI3K, ERK, and protein kinase C (PKC) signaling ([@B133]).

**Table [2](#T2){ref-type="table"}** resumes all current available evidence regarding the role of pro-resolving lipids in *Leishmania* spp. infections. Of note, most of the researches have been focused in CL. Regarding the role of these pro-resolving lipids in CL, RvD1 increases in patients with diffuse CL (DCL), in comparison with those with LCL, who had lower levels of RvD1 and higher levels of RvD2. This RvD1 pattern in DCL patients correlates with higher levels of Arginase-I and TGF-β and lower levels of TNF-α ([@B73]). In an *in vitro* model of *Leishmania* infection based on human cells, RvD1 increased phagocytosis of the *Leishmania* parasites by human macrophages. The increase of RvD1 in *L. amazonensis*-infected macrophages is reversed by baicalein, an inhibitor of 15-LO ([@B73]).

###### 

Experimental evidence on the role of pro-resolving mediators in *Leishmania* spp infections.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Leishmania-induced disease              Host/infection model                                                   Pro-resolving lipid/receptor   Associated inflammatory markers/outcomes          Reference
  --------------------------------------- ---------------------------------------------------------------------- ------------------------------ ------------------------------------------------- -----------
  Cutaneous/mucocutaneous leishmaniasis   DCL patients serum                                                     ↑ RvD1 and ↓ RvD2              ↑ Arginase-I and TGF-β\                           [@B73]
                                                                                                                                                ↓ TNF-α\                                          
                                                                                                                                                ↑ Number of lesions                               

                                          LCL patients serum                                                     ↓ RvD1 and ↑ RvD2              ↓ Arginase-I\                                     [@B73]
                                                                                                                                                ↑ TNF-α Low number of lesions                     

                                          *Ex vivo* model of infection with *L. amazonensis*                     RvD1 treatment                 ↑ Leishmania phagocytosis by human macrophages.   [@B73]

                                          C57BL/6 mice (KO for AhR receptor) infected with *L. major*            ↓ LXA4                         ↑ TNF-α\                                          [@B39]
                                                                                                                                                ↓ IL-12                                           

                                          Human PMNs infected with *L. major*                                    ↓ LXA4                         ↑ LTB4                                            [@B98]

                                          Balb/c mice infected with *L. braziliensis* and serum of ML patients   ↑ Annexin A1                   ↑ NF-κB phosphorylation                           [@B90]

  Visceral leishmaniasis                  Balb/c mice and golden hamster infected with *L. donovani*             15-D-PGJ2 treatment            ↓ Parasite load\                                  [@B136]
                                                                                                                                                ↓ IL-10 and TGF-β\                                
                                                                                                                                                ↑ TNF-α and IL-12                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DCL, diffuse cutaneous leishmaniasis; LCL, localized cutaneous leishmaniasis; ML, mucocutaneous leishmaniasis; RvD1, Resolvin D1; RvD2, Resolvin D2; LXA4, Lipoxin A4; AhR, aryl hydrocarbon receptor; TNF-α, tumor necrosis factor-α; IL, interleukin; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; PMN, polymorphonuclear leukocyte; 15-D-PGJ
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RvD1 and LXA~4~ also target AhR, a transcription factor activated by several tryptophan metabolites and some AA derivatives. AhR has been identified in Treg cells, Th17 cells, and DCs, and its activation induces the expression of IL-10 and TGF-β ([@B55]). In *L. major* infections, the deletion of this receptor accelerates the disease progression, increasing TNF-α production, and decreasing IL-12 and LXA~4~ synthesis ([@B39]).

Annexin A1 is a 37-kDa protein that is expressed under the control of glucocorticoids and activates FPR2/ALXR, increasing IL-10 and IL-6 in experimental models of inflammation (reviewed by [@B97]). In mice infected with *Leishmania \[V\] braziliensis*, Annexin A1 expression is correlated with the lesion size, being higher 2 weeks after infection. Annexin A1 is important to control the inflammatory response while not impairing the immune system's parasite-killing ability. Indeed, Annexin A1-KO mice display more phosphorylation of NF-κB after *L. braziliesis* infection. Also, Annexin A1 is increased in patients with the mucosal form of the disease, but not in those with the localized cutaneous form ([@B90]). In addition, the synthesis of LXA~4~, the primary agonist of FPR2/ALXR, is decreased in PMNs infected with *L. major* ([@B98]). LXA~4~, via FPR2/ALXR activation, enhances the phagocytic activity of PMNs in a dose- and time-dependent manner ([@B143]).

Visceral Leishmaniasis
----------------------

More than 30 years ago, it was reported that *Leishmania donovani* induces the synthesis of PGE~2~ and LTB~4~ in infected macrophages ([@B105], [@B106]). The interaction of *L. donovani* with the TLR2 receptor in macrophages induces activity in the PI3K/Ca^+2^ axis, activating the cytosolic phospholipase A2 enzyme (cPLA2) enzyme, which release AA from membranes. Also, the Ca^+2^ increase activates the nuclear factor of activated T-cells (NFAT2), a transcription factor which translocates into the nucleus and induces the expression of COX-2. Both AA release and COX-2 overexpression are responsible for the resultant increased PGE~2~ release ([@B13]). PGE~2~ is anti-inflammatory, leading to parasite survival via EP~2~ receptor activation. This EP~2~ activation triggers cAMP synthesis, with subsequent PKA activation. This second messenger cascade allows the release of IL-10 and TGF-β and reduces the levels of the inflammatory cytokines TNF-α, IL-12, and IL-17 (**Figure [3](#F3){ref-type="fig"}**). Consequently, the inhibition of COX-2 or EP~2~-mediated activation of PKA enhances the antiparasitic ability of immune cells *in vitro* and *in vivo* ([@B112]).

![Overview of the regulation of inflammatory arachidonic acid (AA) derivatives after *Leishmania infantum* or *Leishmania donovani* infections. Visceral leishmaniasis causative parasites (*L. infantum* and *L. donovani*) induce the production of AA derivatives with opposite roles, depending of the *Leishmania* species. *L. infantum* infection (right panel) induce the release of TNF-α, IL-12, MCP-1 and PGE~2~ from macrophages. PGE~2~, in turn, induce the production of NO•, enhancing parasite killing. In contrast, *L. donovani* (left panel) increase the production of PGE~2~ by magrophages, through the activation of the PI~3~K pathway and the NFAT2 transcription factor. This augmented PGE~2~ activates the EP~2~ receptor in macrophages, inducing the release of regulatory cytokines such as TGF-β and IL-10, thus impairing the immune response against the parasite.](fmicb-09-01961-g003){#F3}

15-D-PGJ~2~, a pro-resolving lipid that acts as an activator of PPAR-γ receptors ([@B33]), decreases the parasite load *in vitro* and *in vivo* (**Table [2](#T2){ref-type="table"}**). This antiparasitic activity correlates with a significant decrease in IL-10 and TGF-β, and a slight increase in the proinflammatory cytokines TNF-α and IL-12, suggesting that 15-D-PGJ~2~ favors the Th1 response against *L. donovani* ([@B136]).

Nevertheless, as in CL, the effect of AA derivatives is also *Leishmania* strain-dependent (**Figure [3](#F3){ref-type="fig"}**). *Leishmania infantum* is a parasite that infects a broad variety of dog populations, inducing canine VL (CVL). This parasite can also infect humans, thus dogs are a reservoir of the disease in large endemic areas of South America ([@B109]). Dogs infected with *L. infantum* show lower levels of PGE~2~ and LTB~4~ compared with uninfected animals. Moreover, lower levels of PGE~2~ and LTB~4~ correlate with an increase in the severity of CVL presentation ([@B126]).

At the cellular and molecular level, PGE~2~ increases parasite killing in macrophages infected with *L. infantum*; this effect is dependent on NO• release ([@B17]; [@B92]). Lymph node-derived leukocytes from dogs infected with *L. infantum* produce higher levels of NO•, TNF-α, and PGE~2~. Consequently, the pharmacological inhibition of PGE~2~ synthesis using indomethacin reduces TNF-α release from these cells ([@B135]). This PGE~2~ release is stimulated by the activation of TLR1/2 receptors by the lipophosphoglycans of *L. infantum*, which induces the PKC-ERK1/2 pathway, causing the release of the Th1 cytokines TNF-α, IL-12, and monocyte chemoattractant protein-1 (MCP-1). In a dog model, PPAR-γ agonists, such as rosiglitazone, inhibit the cytokine storm induction. The fact that Th1 cytokine overexpression is associated with the inhibition of PPAR-γ ([@B67]) concurs with the fact that NSAIDs not only inhibit COX activity but can also activate this transcription factor ([@B66]), adding another possible mechanism of action for the antiparasitic activity of NSAIDs in *in vivo L. infantum* infections (**Figure [3](#F3){ref-type="fig"}**) ([@B92]; [@B135]). Conversely, in an *L. infantum*-resistant mouse model, the animals became sensitive when the activity of 5-LO was prevented. Spleen cells obtained from these mice showed that the IL-17-producing CD4+ T cells were significantly impaired, with a consequent reduction of cytokine release related to the Th17 axis ([@B111]).

In humans presenting with VL, the pattern of cytokines and lipids that drives the inflammatory response is diverse. In a cohort of patients from an endemic area in Brazil, patients with VL had elevated levels of IL-10, IL-6, IL-8, IL-12, RvD1, LTB~4~, and PGF~2α~. Also, these patients had lower levels of TGF-β1 and TNF-α. Moreover, this pattern of immune modulators reverted after treatment with antimonial compounds, increasing the levels of TGF-β1 and decreasing the levels of LTB~4~, RvD1, IL-6, IL-8, and IL-10. This study also showed that TNF-α levels were not modified by chemotherapy treatment, indicating that the inflammatory response to kill the parasite remained unaltered ([@B6]).

*Trypanosoma brucei* INFECTIONS
===============================

*Trypanosoma brucei* subsp. are responsible for human African trypanosomiasis (HAT), also known as sleeping sickness. Currently, HAT is the most neglected disease among the so-called Tri-Tryp (*T. brucei, T. cruzi*, and *Leishmania* spp.) and the volume of research on the inflammatory aspects of the disease are below those for other trypanosomatids. HAT progresses from a hemolymphatic early stage, which is characterized by the presence of parasites in the bloodstream, to a meningoencephalitic or late stage, where the parasite crosses the blood--brain barrier and causes an inflammatory encephalitic reaction that ultimately causes the death of the human host. The early stage (1--3 weeks) begins when the tsetse fly bites its host, depositing parasites held within its saliva on the human skin. Later, the parasites spread to various peripheral organs and tissues via the lymph and blood, inducing symptoms that include general malaise, anemia, weakness, and weight loss. The late stage coincides with the parasite invasion of the central nervous system (CNS), and it is associated with neurological alterations such as sleep disorders, confusion, and mental discoordination. Neuropsychiatric symptoms increase in frequency and severity with disease progression and untreated patients progress to a final stage involving seizures, drowsiness, coma, and death ([@B129]; [@B18]).

Although symptoms are common for both *T. brucei rhodesiense-* and *T. brucei gambiense*-associated HAT, the clinical presentation depends on which of the two subtypes of *T. brucei* is involved in the infection. *T. brucei gambiense* is associated with a slow-progressing form of HAT, whereas *T. brucei rhodesiense* is related to a faster-progressing form that can cause CNS damage within a few weeks of infection ([@B18]). The interplay between the host immune response and parasite subspecies virulence patterns determines the progression and severity of the disease for each particular patient ([@B99]).

The initial response against the parasite mainly involves a Th1 pro-inflammatory cytokine profile including TNF-α, IL-6, NO•, IL-1, and IL-12 ([@B114]). At the same time, *T. brucei gambiense* activates a Th-dependent B-cell response against the main antigenic molecule of *T. brucei*, variant surface glycoprotein (VSG), allowing clearance of the organisms from the blood ([@B76]). As reviewed by [@B99], the presence of VSG allows the immune system to exert a lytic antibody response against *T. brucei*, but the parasite's ability to switch to new VSG coats generates a parasite population that are not recognized by the previously generated antibodies. Although VSG is considered the primary antigenic molecule of *T. brucei*, parasite DNA is released into the plasma of infected mice, acting as a pathogen-associated molecular pattern (PAMP). This DNA activates macrophages in the first days post infection, increasing IL-12 levels, probably to induce a response to control the parasite levels by enhancing Th1 cell polarization ([@B130]). On the other hand, *T. brucei rhodesiense* DNA also increases IL-10 levels, which could play a role in controlling the immune response, as this cytokine has been shown to limit immunopathology ([@B130]; [@B56]).

Common to other trypanosome species, the success of *T. brucei* infection relies on its ability to overcome the initial immune system response but to an extent that is compatible with the life of the host, avoiding a devastating "hyper-infection" ([@B99]). In this respect, resolution of the inflammatory response is one of the main events that *T. brucei* modulates to escape the initial immune system attack. An early study showed that suppressor macrophages obtained from mice infected with *T. brucei* were able to inhibit production of IL-2 and the expression of the IL-2 receptor, decreasing T-cell activation but not pro-inflammatory secretion of IL-1, which could be produced by an increase in PGs ([@B125]). These effects are concordant with following studies reporting that suppressor macrophages control T-cell activation in *T. brucei* infection through NO• synthase (NOS) up-regulation and that elevated NO• produced by macrophages derived from infected mice is also dependent on PG synthesis ([@B114]). At that time, it was clear that PGs had a role in mediating the initial avoidance of the immune system as, in several cell types, *T. brucei* elicited an increase in these eicosanoids; the discovery of a parasite PGF~2α~ synthase further reinforced this idea ([@B3]; [@B64]). In fact, administration of the classic COX inhibitor sodium salicylate (an ASA metabolite) to chronically *T. brucei*-infected Sprague-Dawley rats induced a marked increase in neurotoxicity, with an increase in mRNA levels of pro-inflammatory cytokines such as IL-1β, IL-6, and IFN-γ, and an increase in COX-2 and iNOS enzymes ([@B103]). This evidence suggests that, to some extent, PGs play a role not only in the acute phase of the infection but also in the late stage, probably controlling the parasite burden. In bloodstream forms of *T. brucei rhodesiense*, PGD~2~ and its metabolites can inhibit parasite growth and induce apoptotic-like programmed cell death through ROS generation ([@B41], [@B42]). [@B113] reported that *T. brucei* adenylate cyclases (ACs) play a role in reducing the early innate defense against live parasites by inhibiting TNF-α synthesis in infected mice. The authors demonstrated that cAMP-mediated activation of PKA affected trypanosome infection, an effect mediated by PKA signaling activation ([@B113]). It is well known that PGs can activate cAMP-mediated responses in different cell types; hence, it is possible that these inflammatory mediators could act through these signaling pathways to control parasite survival, although there is no direct evidence for this postulation, at least regarding *T. brucei*.

Another relevant aspect is the control of inflammation and damage to different organs elicited by *T. brucei* in the late stage of the disease. In this respect, the regulatory cytokine IL-10 is induced by the parasite, decreasing the levels of NO• and TNF-α in infected mice, reducing organ damage, and favoring host survival ([@B53]). Also, results from several animal studies indicate that *T. brucei*-induced IL-10 production counters anemia; thus, this cytokine may play a crucial role in parasite and host survival ([@B87]), which concurs with findings from research on human subjects. In the late stage, the levels of IL-10 were found to be elevated irrespective of the geographical location of the patients and the particular genotype of the strain involved in the infection ([@B71]). In a more recent study, [@B60] evaluated plasma and cerebrospinal fluid (CSF) cytokine levels in patients with early- or late-stage HAT. Although the authors did not find a difference in the levels of IFN-γ, TGF-β, IL-6, and IL-10 in the plasma, the CSF samples showed an up-regulation of IL-6 and IL-10 in the late-stage patients, which was associated with a reduction in severity of neurological impairment ([@B60]). In contrast, "trypanotolerant" individuals with elevated IL-10 levels and low levels of TNF-α are associated with a higher risk of developing HAT ([@B58]). This evidence indicates that *T. brucei* can regulate both the inflammatory response in both the early and late stage of the infection, to ensure host survival. Although there is increasing evidence of inflammatory mediators such as cytokines and PGs, the "fine-tuning" of inflammation and parasite survival comprises a series of molecules and processes rather than a single mechanism.

Concluding Remarks
==================

Trypanosomatids in general and *T. cruzi* and *Leishmania* spp. in particular are responsible for chronic disabling and potentially fatal diseases. The understanding of the pathophysiological processes in which the parasite develops is fundamental for the design of much more effective therapies. In this regard, it is very promising to contemplate modifying aspects of the inflammation induced by the parasites in order to resolve or diminish the inflammation, promoting a more efficient clearance of the microorganism by the host's immune system. There is growing evidence addressing this point. Therefore, the use of pro-resolving lipids, mainly ASA-triggered LXs and Rvs, together with antiparasitic therapy itself, could help to prevent the damage induced by the chronic inflammation generated by this group of parasites.

In this context, SPMs such as LXA~4~, RvD1, and drug-induced pro-resolving lipids (such as 13-epi-LXA~4~ and AT-RvD1) have been proven to be effective in the control of the inflammatory response against parasite infection in most animal models. However, the fact that the parasite itself could induce the release of these agents (or eventually synthesize them) indicates that the control of acute inflammation could also be beneficial for the parasite. Thus, the use of SPMs as a strategy against trypanosomatid infections should not be a universal consideration, as the effects of SMPs are highly variable between different parasite species/strains and even different mammals. Overall, there is a need for more research to elucidate which parasites, host conditions, or even infection stages are associated with safe and effective use (or synthesis stimulation) of these SPMs.

Author Contributions
====================

RL-M, AM-B, CC-E, PA-S, LU-L, MP-E, and JM performed the literature search, analyzed the articles, and wrote the manuscript. RL-M and JM made the figures. All authors approved the manuscript in its final version.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** RL-M is funded by the Fondecyt Regular grant \#1160807 (Comisión Nacional de Investigación Científica y Tecnológica, Chile). JM is funded by the Fondecyt Regular grant \#1170126 (Comisión Nacional de Investigación Científica y Tecnológica, Chile), U-REDES grant URC-024/16 (Vicerrectoría de Investigación y Desarrollo, Universidad de Chile, Chile), and CONICYT/REDES grant \#170126 (Comisión Nacional de Investigación Científica y Tecnológica, Chile). CC-E is funded by the PAI grant \#79150077 (Comisión Nacional de Investigación Científica y Tecnológica, Chile). MP-E is funded by the FONDECYT Postdoctoral grant \#3170875 (Comisión Nacional de Investigación Científica y Tecnológica, Chile). The funders had no role in the literature analyses, decision to publish, or preparation of the manuscript.

[^1]: Edited by: Walderez Ornelas Dutra, Universidade Federal de Minas Gerais, Brazil

[^2]: Reviewed by: Keke Celeste Fairfax, Purdue University, United States; Jyothi Nagajyothi, Rutgers, The State University of New Jersey, Newark, United States

[^3]: This article was submitted to Microbial Immunology, a section of the journal Frontiers in Microbiology
